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OBJECTIVES The present study aimed to investigate the influence of endogenous tumor necrosis
factor-alpha (TNF-) that was synthesized during ischemia and exogenous TNF- on
endothelial and inducible nitric oxide synthase (eNOS and iNOS) messenger ribonucleic acid
(mRNA) expression and nitric oxide (NO) production in the isolated rat heart.
BACKGROUND Tumor necrosis factor- is recognized as being a proinflammatory cytokine with a significant
cardiodepressant effect. One of the proposed mechanisms for TNF--induced cardiac
contractile dysfunction is increased NO production via iNOS mRNA upregulation, but the
role of NO in TNF--induced myocardial dysfunction is highly controversial.
METHODS Isolated rat hearts studied by a modified Langendorff model were randomly divided into
subgroups to investigate the effect of 1-h global cardioplegic ischemia or the effect of 1-h
perfusion with exogenous TNF- on the expression of eNOS mRNA and iNOS mRNA and
on NO production.
RESULTS After 1 h of ischemia, there were significant increases in TNF levels in the effluent (from
hearts), and eNOS mRNA expression had declined (from 0.91  0.08 to 0.68  0.19, p 
0.001); but there were no changes in iNOS mRNA expression, and NO was below detectable
levels. Perfusion of isolated hearts with TNF- had a cardiodepressant effect and decreased
eNOS mRNA expression to 0.67 0.04 (p 0.002). Inducible nitric oxide synthase mRNA
was unchanged, and NO was below detectable levels.
CONCLUSIONS We believe this is the first study to directly show that TNF- does not increase NO synthesis
and release but does downregulate eNOS mRNA in the ischemic and nonischemic isolated
rat heart. (J Am Coll Cardiol 2003;42:1299–305) © 2003 by the American College of
Cardiology Foundation
Tumor necrosis factor-alpha (TNF-) is a trimeric 17-kDa
polypeptide produced by monocytes and macrophages,
which are known to be proinflammatory cytokines (1,2). Its
classic trilogy action on the body is the induction of
necrosis, shock, and cachexia. Tumor necrosis factor-alpha
has a potent negative inotropic effect (3,4), and the hemo-
dynamic influence of TNF- is characterized by decreased
myocardial contraction and reduced ejection fraction, hypo-
tension, decreased systemic vascular resistance, and biven-
tricular dilatation (5,6). Recent studies have demonstrated
that TNF- is produced during ischemia-reperfusion injury
and activates nuclear factor kappa-, which initiates the
cytokine cascade and facilitates the expression of chemo-
kines and adhesion molecules (7,8). Experiments with mice
lacking TNF- have demonstrated an improvement in
myocardial ischemia-reperfusion injury (9).
Myocardial cells themselves can produce TNF- in the
isolated perfused heart under endotoxin treatment (10). Our
group previously reported that TNF- is released from the
isolated heart undergoing ischemia and that this cytokine
production is directly correlated with the degree of myocar-
dial dysfunction (11,12). Moreover, the administration of
monoclonal antibodies to TNF- eliminates this cytokine
in effluent and attenuates the postischemic myocardial
injury (13).
One of the mechanisms suggested for TNF- cardiac
contractile dysfunction is increased nitric oxide (NO) pro-
duction by the myocardium, which causes depression of
cardiac function. In the heart, NO is synthesized from
L-arginine by two types of nitric oxide synthases (NOS):
endothelial (eNOS) and inducible (iNOS). A constitutive
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isoform of NOS, eNOS, which is calcium/calmodulin
regulated and was originally described in endothelial cells,
causes continuous NO production and plays an important
role in vascular tone regulation (14). The second type of
NOS described in cardiac myocytes is calcium-independent
iNOS, which can be activated by cytokines, leading to NO
overproduction and causing a negative inotropic effect,
probably by activation of the enzyme guanylate cyclase
(15,16). Some studies have found that cardiac myocytes
express both eNOS and iNOS (16)
Finkel et al. (17) demonstrated that NOS inhibition
prevents the myocardial-depressant effect of TNF- and
concluded that the negative inotropic effect is mediated by
NO. Wang and Zweier (18) observed increased NO and
peroxinitrite release from the isolated rat heart after 30 min
of global ischemia. Pretreatment with the NOS inhibitors
resulted in a fourfold increase in postischemic functional
recovery. The role of NO in TNF--induced myocardial
dysfunction, however, is highly controversial. Avontuur et
al. (19) showed that inhibition of NO synthesis causes
myocardial ischemia in endotoxemic rats. Yocoyama et al.
(4) reported that increased levels of NO did not mediate
TNF--induced myocardial contractile abnormalities. In
another study, TNF- showed no significant effect on NO
production in cultured cardiac myocytes (20). Lastly, NOS
inhibitors did not prevent a decrease of either intracellular
calcium or the amplitude of cell shortening caused by
TNF- in isolated ventricular myocytes (21). Most of these
above-cited studies incorporated evidence provided indi-
rectly by NOS inhibitors.
The present study investigated whether endogenous
(paracrine) TNF- that was synthesized during global
cardioplegic ischemia and exogenous TNF- given in per-
fusion solution have a direct influence on eNOS and iNOS
messenger ribonucleic acid (mRNA) expression and NO
release in the isolated rat heart.
METHODS
Male Wistar rats were anesthetized by intraperitoneal in-
jection of pentobarbital sodium (30 mg/kg). Their hearts
were rapidly excised, immersed in cold saline (4°C),
mounted on the stainless-steel cannula of a modified Lan-
gendorff apparatus, and perfused with Krebs-Henseleit
(KH) solution exactly as detailed in four of our previously
reported studies (11–13).
Left ventricular (LV) hemodynamic parameters (peak
systolic developed pressure) and coronary flow (CF) were
continuously measured at 10-min intervals, and the first
derivative of the rise in LV pressure (dP/dtmax) and time-
pressure integral were calculated.
Ethics. All animals received humane care as described in
“Principles of Laboratory Animal Care” formulated by the
National Society for Medical Research and the “Guide for
the Care and Use of Laboratory Animals” prepared by the
National Academy of Sciences and published by the Na-
tional Institutes of Health (NIH Publication No. 80-23,
revised 1985).
Experimental protocol. The rats were randomly divided
into two subgroups to assess the effect of 1-h global
cardioplegic ischemia on TNF- and NO synthesis and
production. Control measurements were recorded after a
15-min period of stabilization (baseline). All hearts were
perfused thereafter for a 30-min period. Left ventricular
hemodynamic parameters were measured at 10-min inter-
vals. Effluent for TNF- and NO levels was withdrawn at
the end of the 30-min period (n  8). Warm cardioplegia
was then administered for 2 min (37°C, perfusion pressure
73 mm Hg, KCl  16 mEq/l in KH solution) followed by
a 60-min period of global ischemia at 31°C to the arrested
hearts (group A, n  8).
Group B was similar to group A, but these rats received
polyclonal rabbit anti-rat TNF- antibodies (anti-TNF-
Ab, n  8). Concentration of anti-TNF- Ab was selected
according to specific activity: approximately 1 g of these
antibodies completely neutralized 25 pg of rat TNF-. We
found that the TNF- level in effluent was 805  230
pg/ml after a 60-min period of global ischemia. We used 1.5
g/ml of anti-TNF- antibodies (total dose 45 g) for total
neutralization of TNF- in the heart tissue, after which
TNF- was not found in the effluent from the coronary
sinus of ischemic hearts.
The first milliliter of reperfusion effluent was withdrawn
at the end of ischemia to determine TNF- and NO levels
in both groups. Additional hearts were assayed at baseline
(n  7) and immediately at the end of ischemia (n  7 for
each group) to determine LV TNF-, eNOS, and iNOS
mRNA expression.
Two additional subgroups (groups C and D) formed by
other rats were used to investigate the direct effect of
exogenous TNF- on nonischemic perfused hearts. Control
measurements were recorded after a 15-min period of
stabilization. Thereafter, the hearts were perfused for a
60-min period with KH solution to which either saline
(group C, n  10, “controls”) or 16 ng/ml (pathophysio-
logical relevant concentration) TNF- (group D, n  7)
were added to KH solution using an infusion pump (0.5
ml/min). The dose of TNF- was selected according the
results of group A’s postischemic TNF- level measure-
ments. Hemodynamic measurements were recorded every
Abbreviations and Acronyms
CF  coronary flow
eNOS  endothelial nitric oxide synthase
iNOS  inducible nitric oxide synthase
KH  Krebs-Henseleit
LV  left ventricular
mRNA  messenger ribonucleic acid
NO  nitric oxide
NOS  nitric oxide synthase
PCR  polymerase chain reaction
TNF-  tumor necrosis factor-alpha
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10 min, and effluent was withdrawn to determine TNF-
and NO levels. Five hearts in each group were removed for
LV iNOS and eNOS mRNA assays immediately at the end
of the 60-min perfusion period.
TNF- determination. Tumor necrosis factor- levels
were detected in the effluent from the coronary sinus of the
isolated rat hearts. Tumor necrosis factor- activity was
measured using the commercially available enzyme-linked
immunoassay kit Cytoscreen TM rat kit TNF-, Immuno-
assay kit (Biosource, Camarillo, California). The limit of
detection was 4 pg/ml.
NO measurement. Effluent nitrite (NO2)- and nitrate
(NO3)-stable metabolites of NO representing NO produc-
tion were detected in the heart perfusate samples and
cardiac myocyte culture supernatant as described previously
(22). The limit of detection was 2 mol/l.
Myocardial tissue TNF-, eNOS, and iNOS mRNA
determination. Immediately after stabilization (baseline)
or after 1 h of global cardioplegic ischemia, the LV
myocardium was excised and placed in cold Hank’s balanced
solution. Total RNA was extracted from myocardial sam-
ples using the guanidinium thiocyanate method (23). Ribo-
nucleic acid pellets were maintained at 20°C with 75%
ethanol until assay. Dried sediments were dissolved in sterile
RNAse free water and quantitated spectrophotometrically
at   260 nm.
Reverse-transcription polymerase chain reaction (PCR)
amplification and quantitative analysis were prepared as
previously described (12). The primer sequences, annealing
temperature, number of cycles, and PCR product size are
listed in Table 1.
All TNF-, eNOS, and iNOS band intensities were
normalized by respective for glyceraldehyde-phospate dehy-
drogenase values. Each PCR reaction was performed at least
twice, and four to five hearts were used for each experimen-
tal group.
Drugs. Polyclonal rabbit anti-rat TNF- Ab was pur-
chased from R&D Systems (Minneapolis, Minnesota).
Specific activity was as follows: approximately 1 g of these
antibodies completely neutralized 25 pg of rat TNF-.
Recombinant human TNF- was purchased from Repro-
gen Ltd. (Rehovot, Israel).
Statistics. The results are presented as mean  SD. All
hemodynamic measurements were subjected to two-way
analysis of variance with repeated measures. This design
includes one between-subject factor (the experimental
group) and one within-subject factor (the time of measure-
ment). Whenever a significant time trend was demon-
strated, we used contrast analysis to compare each measure-
ment to its successive one (SIMPLE; SPSS Inc., Chicago,
Illinois). Only one contrast was used to eliminate the
problem of multiple comparisons. Student t tests were used
to assess significant differences between relative optical
densities of the mRNA bands in groups and between
groups. Significance was established at p  0.05. All
statistical analyses were performed by the Statistical Depart-
ment at our Medical Center.
RESULTS
The baseline values (groups A and B) for different LV
hemodynamic parameters are given in Table 2. No signifi-
cant differences were found between the experimental
groups. A two-way analysis of variance (comparing group
means and group-time interaction) was conducted to reveal
possible differences in LV hemodynamic parameters for the
experimental groups before cardioplegic ischemia (baseline
values, 10, 20, and 30 min perfusion); none of the p values
attained statistical significance.









Sense CACGCTCTTCTGTCTACTGA 30 57 546
Antisense GGACTCCGTGATGTCTAAGT
eNOS
Sense CCGGAATTCGAATACCAGCCTGATCCATGGAA 45 65 614
Antisense GCCGGATCCTCCAGGAGGGTGTCCACCGCATG
iNOS
Sense GTGTTCCACCAGGAGATGTTG 35 60 576
Antisense CTCCTGCCCACTGAGTTCGTC
GAPDH
Sense AATGCATCCTGCACCACCAA 30 60 515
Antisense GTAGCCATATTCATTGTCAT
eNOS  endothelial nitric oxide synthase; GAPDH  glyceraldehyde-phosphate dehydrogenase; iNOS  inducible nitric oxide synthase; PCR  polymerase chain reaction;
TNF-  tumor necrosis factor–alpha.
Table 2. Baseline Measurements
Group A Group B
Peak systolic pressure 121  4 123  5 (mm Hg)
dP/dtmax (mm Hg/s) 4015  381 4176  174
Time-pressure integral 8.3  0.5 8.5  0.7 (mm Hg  s)
Coronary flow (ml/min) 17.6  0.7 18.6  1.2
Data presented as mean values  SE. All variables were identical for all groups of
hearts (p  nonsignificant).
dP/dt max  first derivative of the rise of left ventricular pressure.
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Effect of global cardioplegic ischemia on TNF-, eNOS,
and iNOS mRNA expression. The baseline TNF-
mRNA expression that had been detected in LV specimens
after a period of stabilization and that did not change after
a 90-min period of nonischemic perfusion served as an
additional control (n  7) to the postischemic TNF-,
iNOS, and eNOS mRNA measurements. Intensities of the
bands at baseline and at the end of perfusion were 0.55 
0.2 and 0.53  0.1, respectively (p  NS, Fig. 1A). One
hour of global cardioplegic ischemia led to a 1.6-fold
increase of TNF- mRNA expression, which was signifi-
cantly higher than the levels detected in nonischemic,
normally perfused hearts (p  0.003, Fig. 1A).
Baseline eNOS and iNOS mRNA expression was de-
tected in LV samples after a period of stabilization and did
not change after a 90-min period of nonischemic perfusion
(Fig. 1B and 1C). No upregulation of iNOS mRNA
expression was registered in postischemic LV myocardial
tissue compared with baseline values or after a 90-min
period of nonischemic perfusion. There was, however, a
significant downregulation of eNOS mRNA expression (p
 0.01, Fig. 1C) after 1 h of global cardioplegic ischemia.
Effect of global cardioplegic ischemia on TNF- and
NO release. Tumor necrosis factor- was not detected in
the myocardial effluent after 15 min of stabilization, before
ischemia (after 30 min of perfusion), or after 90 min of
normal nonischemic perfusion. Significant amounts of
TNF- were detected in the effluent after 1 h of global
cardioplegic ischemia upon the first minute of reperfusion
(805  230 pg/ml). The NO2 and NO3 values in the
effluent from isolated perfused hearts in all groups were
below detectable levels.
Effect of TNF- depletion on myocardial TNF-,
eNOS, and iNOS mRNA expression and release. Anti-
TNF- Ab was added to the cardioplegic solution to
neutralize TNF- in the ischemic heart. In hearts treated
with anti-TNF- Ab, TNF- mRNA expression was at
basal levels after 1 h of global ischemia (Fig. 1A), which was
significantly lower than the levels detected in untreated
ischemic hearts.
There was an increase of eNOS mRNA in the ischemic
heart pretreated with anti-TNF- Ab compared with un-
treated ischemic hearts (1.07  0.1 and 0.67  0.2,
respectively, p  0.01). There were no significant differ-
ences in iNOS mRNA band intensities between anti-
TNF- Ab-treated and control hearts (Fig. 1B and 1C).
Tumor necrosis factor- protein production and NO2 and
NO3 in the effluent from the ischemic hearts treated with
anti-TNF- Ab were below detectable levels.
Effect of exogenous TNF- on LV hemodynamic per-
formances. No significant differences in baseline values for
LV hemodynamic parameters were found between groups
C and D (Fig. 2). Hearts treated with TNF- demonstrated
a significant deterioration in all hemodynamic measure-
ments after only 10 min of perfusion (Fig. 2) and, after 60
min of TNF- treatment, peak-systolic pressure fell to 45.1
Figure 1. Effects of global cardioplegic ischemia on myocardial tumor
necrosis factor- (TNF-) (A), endothelial nitric oxide synthase (eNOS)
(B), and inducible nitric oxide synthase (iNOS) (C) mRNA expression:
relative optical densities of polymerase chain reaction signals. Data were
normalized to the glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
polymerase chain reaction signal. Shown are samples of left ventricular
myocardium withdrawn at the end of stabilization [1], after ischemia [2],
after ischemia with anti-TNF- antibodies in the cardioplegia [3], and
after 90 min of normal nonischemic perfusion [4].
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 3.7%; dP/dtmax to 51.8  5.5%, time-pressure integral to
73.5  4.8%, and CF to 54.7  2.8% (p  0.001 for all
measurements compared with baseline). The decrease of LV
function parameters in TNF--treated hearts was signifi-
cant compared wit untreated hearts (Fig. 2, p  0.0001 for
all measurements).
Effect of exogenous TNF- on eNOS and iNOS mRNA
expression. Endothelial nitric oxide synthase mRNA ex-
pression in LV specimens after a period of stabilization did
not change after a 60-min period of nonischemic perfusion,
but 60 min of TNF- treatment led to significant down-
regulation of eNOS mRNA expression (Fig. 3A; p 0.01).
There were no significant differences in iNOS mRNA band
intensities between TNF--treated and control hearts
(Fig. 3B).
DISCUSSION
In the present study, we have demonstrated that endoge-
nous (i.e., released during ischemia) and exogenous TNF-
cause depression of LV function associated with undetect-
able NO levels in the effluent from the heart, unchanged
iNOS mRNA expression, and eNOS mRNA downregula-
tion.
The role of TNF- in cardiac dysfunction. Tumor ne-
crosis factor- is an essential mediator of the profound
cardiovascular changes observed during the shocked state
associated with bacterial sepsis and its experimental coun-
terpart, endotoxic shock (24,25). Recent investigations have
confirmed that the TNF- levels were increased in patients
with congestive heart failure and demonstrated a direct
relationship between circulating levels of TNF- and clin-
ical features of the disease (26). Tumor necrosis factor-
also plays an important role in reperfusion injury after
myocardial revascularization (27). Tumor necrosis factor-
is synthesized and released from the isolated heart under-
going ischemia (11,12). The results of current experiments
support this previous observation. Immunohistochemical
studies localized TNF- in ischemic hearts to cardiac
myocytes and endothelial cells (13). The myocardium has
been shown to be a major source of TNF- in patients
undergoing cardiopulmonary bypass (in vivo acute global
Figure 2. Effect of exogenous tumor necrosis factor- on hemodynamic performance of isolated rat hearts during 1 h of perfusion: control group (open
circles) and hearts treated with tumor necrosis factor- (black circles), p  0.0001 (analysis of variance) for all measurements vs. control.
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ischemia) (28). A blood-free model was intentionally used
in this study to exclude the possibility of involvement of
systemic blood factors in endogenous TNF- and NO
formation and in exogenous TNF- action on the heart. A
model of cardioplegic ischemia was chosen because of the
extensive use of cardioplegic solutions in cardiopulmonary
bypass.
The cardiac depressant effect of TNF- on an isolated
myocardium was previously shown with relatively high
concentrations of this cytokine (17,29). In the present study,
perfusion with TNF- in a low, pathophysiologically rele-
vant concentration led to a significant decrease of LV
peak-systolic pressure, dP/dtmax, and time-pressure integral.
Mechanisms of TNF- action. The exact mechanisms
responsible for TNF--induced cardiac damage are contro-
versial (30). Several mechanisms have been suggested to
cause TNF--induced myocardial dysfunction. Tumor ne-
crosis factor- decreases the intracellular free calcium and
leads to dysfunctional excitation-contraction coupling, caus-
ing systolic/diastolic dysfunction (4,21). Several in vitro and
in vivo studies have shown involvement of sphingosine in
TNF--mediated cardiac depression (29,31). Tumor necro-
sis factor- induces apoptosis (programmed cell death) in
various cell types, including cardiac myocytes (2,31). Other
possible mechanisms are direct cytotoxicity and oxidant
stress (30).
Current hypothesis. Some previous studies using NO
synthesis inhibitors confirm that NO is responsible for
TNF--induced negative inotropism (17,18). It is proposed
that TNF- stimulates iNOS which, in turn, controls the
conversion of L-arginine to NO. Excessive production of
NO by cardiomyocytes causes contractile dysfunction and
depression of cardiac function.
Recent investigations, however, have shown that the
NOS inhibitors do not ameliorate the decreased contractil-
ity of isolated perfused hearts observed with TNF- (29).
Tumor necrosis factor- had no significant effect on NO
and cGMP production in cultured cardiac myocytes (20). In
a model of isolated cardiac myocytes, NOS inhibitors do not
attenuate the negative inotropic effect of TNF-, and
incubation with TNF- did not increase NO and cGMP
production (4). NOS inhibitors did not prevent a decrease
in either intracellular calcium or the amplitude of cell
shortening caused by TNF in isolated ventricular myocytes
(21). In addition, it has been shown that the massive
cardiospecific overexpression of iNOS in transgenic mice is
not associated with deleterious effects on cardiac hemody-
namics and energetics (32). The participation of eNOS
mRNA expression in cardiodepressant action of TNF- has
not been investigated in depth.
New insights. The present study clearly has demonstrated
that endogenous (paracrine) TNF- synthesized during 1 h
of global cardioplegic ischemia or exogenous TNF- added
for 1 h to perfusion solution does not increase iNOS mRNA
expression and NO release in the isolated rat heart. In the
present study, we have demonstrated that the endogenous
and exogenous TNF- caused a decrease in eNOS mRNA
expression. Moreover, depletion of TNF- with anti-
TNF- Ab resulted in an increase in eNOS mRNA in the
ischemic heart compared with untreated ischemic hearts,
recovering eNOS mRNA expression to baseline levels.
We have shown that CF significantly decreased after 1 h
of perfusion with a TNF--containing solution. Previous
experiments demonstrated that TNF- caused coronary
constriction in the rat heart, which might accentuate direct
negative inotropic action of TNF- (29). In the current
study, we found that eNOS mRNA downregulation in
hearts undergoing ischemia or TNF- perfusion may lead
to a decrease in endothelial NO production, coronary
vasoconstriction, and a decrease of CF. This might be one
of the possible mechanisms of TNF--induced cardiode-
pressant action. It is theoretically possible that a more
prolonged (3 to 6 h) TNF- influence could lead to a
change in iNOS mRNA expression, but this duration would
be considered excessive in a model such as ours.
Study limitations. Our study had several limitations. First,
it was performed in vitro. Second, nonblood perfusion
Figure 3. Effect of exogenous tumor necrosis factor- on myocardial
endothelial nitric oxide synthase (eNOS) (A) and inducible nitric oxide
synthase (iNOS) (B) messenger ribonucleic acid expression: relative optical
densities of polymerase chain reaction signals. Data were normalized to
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) polymerase chain
reaction signal. Samples of left ventricular myocardium withdrawn at the
end of stabilization [1], after 1-h perfusion with normal Krebs-Henseleit
solution [2], and after 1 h of perfusion with tumor necrosis factor- [3].
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excluded an influence of blood immunological and proin-
flammatory factors and also excluded the influence of several
types of blood cells that are an important source of TNF-
and NO. Caution must be exercised when drawing direct
clinical conclusions from the use of anti-TNF- Ab in a
clinical setting because our study was performed on an
isolated rat heart model.
Conclusions. This study demonstrated that endogenous
(i.e., released during ischemia) and exogenous TNF- do
not influence iNOS mRNA expression and that they do not
enhance NO release. This study did reveal eNOS mRNA
downregulation in the isolated rat heart. Depletion of
endogenous TNF- caused by anti-TNF- Ab led to the
decrease of TNF- mRNA expression, the elimination of
TNF- protein from effluent solution, and an increase in
eNOS mRNA expression to baseline levels in ischemic
hearts. These findings suggest that eNOS downregulation
occurs as a result of endogenous TNF- synthesis. We
hypothesize that the TNF--related eNOS mRNA down-
regulation that is associated with CF decreases and that LV
dysfunction may be one of the mechanisms of TNF--
mediated myocardial depression.
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